To assess the accuracy and utility of routine multiparametric magnetic resonance imaging (mpMRI) and transperineal template-guided prostate biopsy (TPB) after enrolment in active surveillance (AS).
Introduction
Active surveillance (AS) has emerged as a management strategy for treating men with low-risk prostate cancer [1, 2] . Traditional AS protocols rely on a combination of DRE, serial PSA estimation and interval TRUS-guided biopsy. AS is associated with low rates of prostate cancer-specific mortality, but up to one-third of men eventually receive radical treatment with curative intent, and a small but significant minority of men develop metastatic disease and die from prostate cancer [3] [4] [5] [6] [7] . Such adverse outcomes are believed to be attributable to an inability to accurately identify aggressive disease at presentation, or a failure to detect clinical progression whilst under surveillance. In contrast to the original pathological localization studies described by McNeal in 1968 [8] , contemporary data from radical prostatectomy cohorts [9, 10] , radiological localization studies [11] [12] [13] and mature AS series [3] [4] [5] [6] [7] consistently show that prostate cancer is more commonly located in the anterior prostate, suggesting that reliance on TRUS biopsy alone is insufficient to accurately risk-stratify men entering AS. Subsequent AS protocol modifications designed to address this discrepancy have focused on the role of multiparametric (mp)MRI as an adjunct to standard TRUS biopsy [14, 15] ; however, although mpMRI is associated with high negative predictive values for Gleason primary pattern 4 prostate cancer, it has a much lower reported sensitivity for lesser grades of prostate" cancer, even in the hands of dedicated uro-radiologists with an interest in prostate cancer [12, 13, 16] . One alternative approach is systematic transperineal template-guided prostate biopsy (TPB). TPB allows comprehensive survey of the entire prostate, and has been shown to reflect subsequent radical prostatectomy specimen pathology more accurately than TRUS biopsy [17] , yet, despite widespread adoption for diagnostic purposes, very few studies have explored its role in accurately stratifying men entering AS. In the present study, we review the published literature to date, and describe our experience using routine mpMRI and TPB to prospectively risk-stratify consecutive men entering AS at our institution.
Patients and Methods

Patient Selection Criteria
In April 2012 the AS protocol at our institution was modified to include early mpMRI and routine TPB within the first 12 months of diagnosis on TRUS biopsy. Eligibility criteria comprised predicted life expectancy ≥10 years; Gleason score ≤3 + 4; clinical stage T1-T2; PSA ≤ 15 ng/mL; <50% positive biopsy cores. All men with low-risk disease according to the D'Amico criteria (Gleason score 6, PSA ≤ 10 ng/mL, T1c-T2a) [18] were offered AS as a primary treatment option. Those with D'Amico intermediate-risk disease (low-volume Gleason score 7, PSA 10-15 ng/mL, T2b) were offered AS as an alternative to radical treatment.
Multiparametric MRI
Multiparametric MRI scanning was performed a minimum of 3 months after TRUS biopsy to mitigate against the confounding effects of post-biopsy haemorrhage. Patients underwent a standardized mpMRI with 1.5-Tesla magnetic field strength and a pelvic phased-array coil. T1-, T2-and diffusion-weighted imaging was obtained in all cases and, after an early protocol amendment, dynamic gadolinium contrast-enhanced imaging sequences were acquired in 169 cases (81.3%). All scans were reported by one of two dedicated consultant radiologists with experience in reporting prostate mpMRI, according to the European Society of UroRadiology Prostate Imaging Reporting and Data System (PI-RADS) v.1 (2012-2014) and v.2 (2015-) classification systems [19] .
Transperineal Template Prostate Biopsies
The TPBs were performed as day-case procedures under general anaesthesia, using antibiotic prophylaxis and perineal infiltration with bupivacaine/adrenaline. Men without contraindications also received peril-procedural a-blockade to mitigate against postoperative urinary retention. Transperineal biopsies were performed using a Hitachi Arietta V70 transperineal probe (Hitachi Medical Systems, Wellingborough, UK) and Classic STEPPER TM device (CIVCO, Kalona, IA, USA) according to a novel 10-sector template (Fig. 1) . The longitudinal sagittal break was orientated at the midpoint of the distance between the prostate apex and base for prostate glands >2 cm in length.
Where the prostate length was <2 cm, a single longitudinal biopsy was taken. Systematic biopsies were taken using a Bard Max-Core TM 18-G needle directed at 5-mm intervals via a standard brachytherapy grid in all cases. Targeted biopsies were not performed. In this way the number of obtained cores was directly related to prostate size. Harvested prostate biopsies were retained, processed and analysed separately to preserve location-specific pathological reporting.
Statistical Analyses
Statistical analyses were performed using SPSS v. 18 statistical software (SPSS Inc.,Chicago, IL, USA) Normally distributed data were compared using Student's t-test, while nonGaussian data were compared using the Mann-Whitney Utest. Nominal and ordinal data were compared using the chisquared test. interval between TRUS biopsy and mpMRI was 3.0 months. A total of 62 men had evidence of post-biopsy haemorrhage on MRI, and in nine cases, an overall PI-RADS score was not recorded as a result of severe artefact.
Results
Between
The median interval between TRUS biopsy and TPB was 9.9 months, with a mean PSA of 5.9 (0.8-13.9) ng/mL at TRUS biopsy and 6.1 (0.7-20.5) ng/mL at TPB. The median (range) number of TPB cores was 50 (17-161), with a mean TPB core density of 1.2 cores/cm 3 prostate volume. The complication rate after TPB was 27/208 (12.9%), including 15 (7.2%) acute urinary retention events, seven (3.4%) haematuria/clot retention events, four fever (1.9%) events and one UTI (0.48%). There were no Clavien-Dindo grade 3-5 complications and no readmission within 30 days of surgery. One man required interval TURP for refractory urinary retention after TPB.
Overall, 83 men (39.9%) were upgraded at TPB, including 76 (38.8%) with Gleason 3 + 3 disease and seven (58%) with Gleason 3 + 4 disease. Of these, 26 (31.3%) were found to harbour primary pattern Gleason grade ≥4. The overall median (interquartile range) positive core length was 4 (2-7) mm and the mean (AESD) core positivity rate was 10 (10)%. Sites of upgrading are shown in Fig. 1 . Upgrading was significantly more common at the prostate apex vs prostate base (95 vs 57 cores; P < 0.001). There was no significant difference in upgrading in the anterior and posterior prostate as a whole (lateral zones excluded), but when the apical and basal sectors were compared individually, upgrading was similar for the anterior and posterior apex (45 vs 50; P < 0.66), but more commonly seen at the anterior vs posterior base (33 vs 24 cores; P < 0.09).
A total of 49 men had bilateral disease at TRUS biopsy, of whom 32 (65.3%) were bilateral after TPB. Conversely, 79 men had bilateral disease at TPB, of whom 32 (40.5%) were bilateral at TRUS biopsy. Predictors of upgrading were PSA at TRUS biopsy (6.5 vs 5.4; P < 0.001), PSA density (0.19 vs 0.15; P < 0.001) and >1 positive TRUS biopsy core (51% vs 30%; P < 0.009). One man with Gleason 3 + 4 cancer at TRUS biopsy was found to harbour only Gleason 3 + 3 disease on TPB. In 23 men (11.1%) no cancer was identified at TPB: all 23 men had low-risk disease according to the D'Amico criteria (Gleason score 6, PSA ≤ 10 ng/mL, T1c-T2a) [18] and 19 men had very-low-risk prostate cancer fulfilling Epstein criteria (Gleason score 6, PSA < 10 ng/mL, ≤T1c) [20] . Figures 2 and 3 show TPB outcomes for men with Gleason 3 + 3 and Gleason 3 + 4 disease, stratified by mpMRI findings. Using TPB as a reference standard, with a PI-RADS score ≥3 indicating a positive scan, the sensitivity and specificity of mpMRI varied depending on the definition of clinically significant prostate cancer used. For Gleason ≥4 + 3 disease or any cancer core length ≥6 mm (the definition used in a recent multicentre paired cohort study [16] ), sensitivity was 74.2% and specificity was 57.1%. A less stringent secondary definition for clinically significant prostate cancer of any core of Gleason ≥3 + 4 was associated with a sensitivity and specificity of 67.9% and 33.9%, respectively (Table 2) . In this study all men received TPB irrespective of mpMRI findings: if a hypothetical PI-RADS score of ≥3 were used to stratify the need for TPB, 24/83 (28.9%) of upgraded cases would have been missed, including two cases with Gleason 4 + 3, two with Gleason 4 + 4, and one with Gleason 4 + 5 disease. Of these 14/24 men (58.3%) had a PSA density of >0.15, including four out of five men with Gleason score ≥4 + 3 disease.
Of 125 men with stable disease at TPB, 123 (98.4%) remained on AS, including all those with benign pathology or Gleason 3 + 3 disease. One man each with stable persistent lowvolume Gleason score 3 + 4 prostate cancer underwent radical prostatectomy and radical radiotherapy through their own choice. Of 86 men upgraded at TPB, seven men with low-volume Gleason score 3 + 4 and one man with Gleason score 4 + 3 disease declined radical treatment in favour of continued AS. The remainder underwent radical treatment as outlined in Table 3 . Of the 37 men who underwent radical prostatectomy, 28 (75.7%) had a final Gleason score that was concordant with TPB, five were upgraded (all from Gleason score 3 + 4 to Gleason score 4 + 3) and four were downgraded (two from Gleason score 4 + 3 to Gleason score 3 + 4, one from Gleason score 4 + 4 to Gleason score 4 + 3 and one from Gleason score 3 + 4 to Gleason score 3 + 3). Overall there was a change in prostate cancer management after TPB for 77/208 men (37.0%) after TPB.
Discussion
Traditional AS protocols are associated with very low reported rates of prostate cancer-specific mortality, yet up to one-third of patients ultimately undergo delayed treatment, and a small but significant number of patients will develop metastatic disease [3] [4] [5] [6] [7] . In the largest study of its kind to date, Klotz et al. [3] reported outcomes for 993 men managed by AS with a median follow-up of 6.4 years. The intervention rate was 27%; 13 men developed metastatic prostate cancer, and a further 15 died from the disease. Subsequent analyses have shown that misclassification at diagnosis, rather than disease evolution or progression, was the likely cause of treatment failure, with the anterior prostate suggested as the primary location for tumour upgrading [3, 7] . It is already well established that TRUS biopsy is frequently discordant with final radical prostatectomy pathology, as shown in a study of 4 885 radical prostatectomy specimens, which reported rates of upgrading of 39-56% in men undergoing surgery for presumed low-risk organ-confined disease [10] . In this study the anterior prostate was again the primary location of tumour upgrading.
It is known that TPB is more closely correlated with radical prostatectomy pathology than TRUS biopsy [17] and it has shown high rates of cancer detection in patients with multiple previous negative TRUS biopsies [21] , but relatively few studies have explored the role of TPB for risk classification in AS (Table 4 ). Of the five published studies to date, all have reported significant rates of tumour upgrading when compared with conventional TRUS biopsy, ranging from 29% to 46% [17, [22] [23] [24] [25] . All were retrospective studies of mixed populations of men undergoing TPB, using a variety of transperineal sampling techniques. In the largest study to date, Vyas et al. [25] reported tumour upgrading in 29% of 307 men on AS from a cohort of 634 mixed patients undergoing TPB. Unfortunately, the location of tumour upgrading was not reported and, because of resource issues, only a limited TPB was performed. In contrast Ayres et al. [22] described results from a retrospective cohort of 101 men entering AS for presumed low-risk prostate cancer, in whom an extended TPB was performed. The mean number of prostate biopsies at TPB was 47, with a mean ratio of biopsies to prostate volume of 1.04, suggesting comprehensive prostate gland sampling. The reported rate of tumour upgrading was 34%, but the location of tumour upgrading was not addressed. Studies by Thompson et al. [17] and Pham et al. [23] retrospectively compared differing biopsy techniques: the former compared saturation TRUS with a limited TPB and the latter compared limited with extended TPB. Neither specifically described sites of tumour upgrading. Indeed the only previous study to report location-specific upgrading is that of Taira et al. [24] , who described rates of upgrading in 64 men with Epstein criteria very-low-risk prostate cancer entering an AS protocol. In that small retrospective study, 39% of men were upgraded to 'clinically significant disease' after extended TPB, with the anterior prostate and prostate apex cited as the location of upgrading in the majority of cases.
In the present study, we report data from a series of 208 consecutive men prospectively enrolled into an AS programme which involved mpMRI followed by comprehensive location-specific mapping TPB within 12 months of diagnosis. As such, it represents the largest study of its kind to date. As in the study by Taira et al. [24] , common sites of upgrading were the anterior prostate base and prostatic apex, areas typically missed by conventional TRUS biopsy. In all, 39.9% of patients were upgraded, of whom almost one-third had primary Gleason pattern 4 disease, resulting in a change in prostate cancer management in a little over one-third of cases. While these results are broadly in line with previously reported studies, a misclassification rate of almost 40% is towards the higher end of the spectrum and is likely to be attributable to a number of factors. Firstly, we employed an extended TPB technique similar to that described by Ayres et al. [22] , leading to a comprehensive TPB core density of 1.2 cores/cm 3 prostate volume, suggesting comprehensive survey of the prostate. A second consideration is that AS enrolment criteria were more inclusive than in previously reported studies, more closely reflecting the Toronto [3] and PRIAS [4] cohorts. Virtually all men with Gleason score 3 + 3 prostate cancer were enrolled into AS, provided they consented to an mpMRI and TPB. As shown in Table 5 , when the data were stratified for increasingly stringent AS selection criteria, rates of misclassification fell accordingly. Nevertheless, even when AS inclusion was restricted to the most stringent Epstein criteria NPV, negative predictive value; PPV, positive predictive value. *Lesions identified on multiparametric MRI as PI-RADS score ≥3 were considered positive. [20] , almost one-quarter of men were still found to harbour higher grade prostate cancer than initially suspected.
Recent AS protocol modifications, designed to improve riskstratification, have included early and repeat mpMRI scanning [14, 15] , yet few studies have analysed its diagnostic accuracy in AS populations when compared with systematic TPB as a reference standard.
In the present study we found an overall sensitivity and specificity of 74.2% and 57.1%, respectively, for the identification Gleason score ≥4 + 3 disease or any cancer core length ≥6 mm. These rates are lower than those described in the recently published PROMIS trial [16] , which used a similar definition, although this difference may be partially explained by the lower overall prevalence of prostate cancer in the undiagnosed pre-biopsy population in the latter trial. We also used the previous PI-RADS v1 classification until the publication of an update in 2015, which may have also contributed to some of the observed difference. Perhaps the most pertinent question is whether improved stratification at diagnosis will result in an overall improvement in cancer-specific survival for men entering AS. It is possible, for example, that TPB merely selects out tumours which will ultimately declare themselves during the surveillance period, either on serial TRUS biopsy survey, or via PSA kinetics, without detriment to the overall chances of cancer cure. Certainly transperineal template-guided prostate biopsy is expensive, time-consuming, requires general anaesthetic, and is associated with a higher rate of complications than conventional TRUS biopsy [25, 26] . It is, however, wellestablished that PSA velocity and PSA doubling time are unreliable markers in an AS setting [27, 28] , and the finding of occult tumours in the anterior and apical prostate suggest further random TRUS biopsy survey of the prostate may not be an effective way of detecting 'clinical progression'. In addition, perhaps the most compelling argument for accurate stratification at diagnosis is the finding of significant rates of high grade disease in this study. Of 196 men with supposed low-risk prostate cancer, 19 (9.7%) were found to harbour at primary pattern ≥4 disease, of whom five had Gleason score 8-10 disease. Although we cannot assume improved oncological outcomes resulting from accurate classification of these patients, it is well established that Gleason grade at diagnosis is a key prognosticator of prostate cancer-specific survival, and it is unlikely that many clinicians would argue against the opportunity to offer such patients attempted curative treatment. Ultimately, the only way to truly answer such a question would be a randomized controlled trial with extended follow-up, comparing conventional AS regimes with more modern protocols focused on accurate classification at diagnosis. Given the long lead time, rapidly evolving diagnostic field, and patient expectations, it is questionable whether such a study could ever be performed. Nevertheless, the results from this study show that early comprehensive transperineal template-guided prostate biopsy identifies a significant proportion of patients with higher grade disease who are suitable for radical treatment.
